In this phase I/IIa study, local AdCD40L immunostimulatory gene therapy was shown to be well tolerated in patients with malignant melanoma.

Loskog A, Maleka A, Mangsbo S, Svensson E, Lundberg C, Nilsson A, Krause J, Agnarsdóttir M, Sundin A, Ahlström H, Tötterman TH, Ullenhag G

Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients.

Br J Cancer. 2016 Apr 12;114(8):872-80


Featured publications